“…High-throughput drug screening and computer-aided drug design have identified an array of TMEM16A activators and potentiators, among which ETX001, a potentiator of TMEM16A, has entered clinical trials as therapeutic agent for cystic fibrosis ( 7 ). Meanwhile, a large number of TMEM16A inhibitors have been identified, including natural products Cepharanthine ( 8 ), Evodiamine ( 9 ), Honokiol ( 10 ), and Luteolin ( 11 ) and synthetic compounds Ani9 ( 12 ), CaCC inh -A01 ( 13 ), T16A inh -A01 ( 14 ), Monna ( 15 ), and 4-arylthiophene-3-carboxylic acid ( 16 ). These inhibitors have shown potential therapeutic effects in the laboratory against TMEM16A-related diseases such as hypertension, cancer, and secretory diarrhea ( 7 ).…”